JP2013532176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532176A5 JP2013532176A5 JP2013519027A JP2013519027A JP2013532176A5 JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5 JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii variant
- recombinant fviii
- amino acid
- recombinant
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 21
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 21
- 238000000338 in vitro Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000009881 electrostatic interaction Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169592.2 | 2010-07-15 | ||
| EP10169592 | 2010-07-15 | ||
| US36547810P | 2010-07-19 | 2010-07-19 | |
| US61/365,478 | 2010-07-19 | ||
| PCT/EP2011/061349 WO2012007324A2 (en) | 2010-07-15 | 2011-07-06 | Stabilized factor viii variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532176A JP2013532176A (ja) | 2013-08-15 |
| JP2013532176A5 true JP2013532176A5 (enExample) | 2014-08-21 |
Family
ID=42797590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519027A Ceased JP2013532176A (ja) | 2010-07-15 | 2011-07-06 | 安定化させた第ｖｉｉｉ因子バリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20130183280A1 (enExample) |
| EP (1) | EP2593130A2 (enExample) |
| JP (1) | JP2013532176A (enExample) |
| CN (1) | CN102971006A (enExample) |
| WO (1) | WO2012007324A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| CN111548418A (zh) * | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US20150045303A1 (en) * | 2012-04-24 | 2015-02-12 | Novo Nordisk A/S | Pharmaceutical Composition Suitable for Treatment of Haemophilia |
| JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第ｖｉｉ因子コンジュゲート |
| UY35343A (es) * | 2013-02-26 | 2014-09-30 | Bayer Healthcare Llc | Formulaciones y procedimientos para la producción de proteína recombinante aumentada |
| HRP20210031T1 (hr) | 2013-06-24 | 2021-05-14 | Weidong, Xiao | Pripravci i metode mutantskog faktora viii |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| CA2927756A1 (en) | 2013-10-15 | 2015-04-23 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
| EP3058362B1 (en) * | 2013-10-18 | 2019-01-02 | Dr. Reddy's Laboratories Limited | In-vitro method for determining fate of polypeptide variant |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| JP6516829B2 (ja) | 2014-08-04 | 2019-05-22 | シーエスエル、リミテッド | 第ｖｉｉｉ因子製剤 |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| WO2021084276A2 (en) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii construct |
| WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| WO2022063887A1 (en) * | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| DE69936409T2 (de) | 1998-04-28 | 2008-04-17 | Laboratoires Serono S.A., Coinsins | Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide |
| EP1421539B1 (en) | 2001-06-14 | 2009-10-28 | The Scripps Research Institute | Stabilized factor viii with engineered disulfide bonds |
| EP2292273A3 (en) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| JP5235657B2 (ja) | 2005-03-24 | 2013-07-10 | バイオジェネリックス ゲーエムベーハー | 原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現 |
| US20080227691A1 (en) * | 2005-04-01 | 2008-09-18 | Novo Nordisk Health Care Ag | Blood Coagulation FVIII Analogues |
| US8633300B2 (en) * | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| WO2006134174A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Dimeric and multimeric fviia compound |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| CN101516388B (zh) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| PT2349342T (pt) * | 2008-10-17 | 2018-10-26 | Baxalta Inc | Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água |
-
2011
- 2011-07-06 JP JP2013519027A patent/JP2013532176A/ja not_active Ceased
- 2011-07-06 WO PCT/EP2011/061349 patent/WO2012007324A2/en not_active Ceased
- 2011-07-06 CN CN2011800348298A patent/CN102971006A/zh not_active Withdrawn
- 2011-07-06 EP EP11735405.0A patent/EP2593130A2/en not_active Withdrawn
- 2011-07-06 US US13/808,204 patent/US20130183280A1/en not_active Abandoned
-
2016
- 2016-06-01 US US15/170,502 patent/US20160264645A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Functionalization of graphene oxide generates a unique interface for selective serum protein interactions | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| WO2009087082A3 (de) | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil | |
| AR119682A2 (es) | Composiciones inmunogénicas de antígenos de staphylococcus aureus | |
| RU2019124678A (ru) | Слитый белок pd1-41bbl и способы его применения | |
| CR11561A (es) | Proteinas de union a antigenos | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| MA37983A1 (fr) | Analogues du glucagon | |
| CR20210076A (es) | Composiciones de anticuerpo fcrn | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| HRP20220214T1 (hr) | Imunomodulacijska sredstva | |
| IN2012DN03368A (enExample) | ||
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| NZ705384A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| IN2014KN01713A (enExample) | ||
| WO2011036443A3 (en) | Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| JP2012115277A5 (enExample) | ||
| ES2675847T3 (es) | Nuevo anticuerpo anti-DR5 | |
| WO2012018767A3 (en) | Antibodies directed against il-17 |